Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Universitë De Bordeaux

Université Paris Diderot-paris 7

Université De Paris

Universite Paris Xiii Paris-nord

Chu De Bordeaux

Université Paris Diderot

Inserm

Xavier Treton

Eric Ogier-Denis

Yoram Bouhnik

Alain Couvineau

Thierry Voisin

Nassima Messal

David Laharie

Fanny Daniel

Gilles Wainrib

Cecile Guichard

Eric Pedruzzi

Mathieu Uzzan

Yann Harnoy

Ian Morilla

Cécile Guichard

The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.

Methods for predicting acute severe colitis treatment response

The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.

Method of treating an inflammatory bowel disease comprising agonists of orexin-1 receptor

The present invention relates to a non human model animal for ulcerative colitis and its main complications such as primary sclerosing cholangitis and colorectal cancer. More particularly, the present invention relates to a transgenic non human animal model for ulcerative colitis and its main complications such as primary sclerosing cholangitis, and colorectal cancer comprising a targeted disruption in the IL10 and NOX1 genes so that IL10 and NOX1 are not expressed in said animal.

Non human animal model for ulcerative colitis and its main complications

Growing community of inventors

Paris, France

Xavier Treton